Hemab Therapeutics Holdings, Inc. (COAG) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-06

Key Insights

Novo Holdings A/S, a 10% owner and director of Hemab Therapeutics, acquired 4,180,550 common shares on 05/04/2026 through automatic conversion of preferred stock in connection with the company's IPO closing.
The transaction involved conversion of multiple preferred stock series (Seed, Series A, B, and C) into common stock on a 22-for-1 basis with no additional consideration paid, representing a significant pre-IPO to public equity transition.
This is a routine IPO-related conversion activity rather than a discretionary insider buy or sell, indicating Novo Holdings maintained its substantial ownership stake through the public offering process at an IPO closing.

Want the newest filings?

This analysis covers the filing from 2026-05-06. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-05-04

CFO and General Manager Mads Nikolaj Behrndt-Eriksen received 195,206 warrant shares at $6 exercise price and 49,016 stock options at $18 exercise price, representing significant equity compensation grants in January and April 2026.
Both equity awards have standard 4-year vesting schedules, with warrants vesting 25% upfront on January 1, 2027 followed by monthly installments, and options vesting monthly from May 2026 through May 2030, indicating long-term retention incentives.
No direct stock purchases or sales by the insider are reported in this filing, only new grant issuances, suggesting the company is using equity compensation as a retention tool rather than indicating insider confidence through open market buying.
The exercise prices ($6 for warrants, $18 for options) suggest the company granted these awards at potentially significant premiums to current trading levels, typical for new officer compensation packages.

Filed: 2026-05-04

Chief Medical Officer Catherine Madigan received 145,134 warrant shares at $6 exercise price with 4-year vesting starting January 29, 2026, indicating equity compensation for executive retention and alignment with company performance.
Additional stock option grant of 49,016 shares at $18 exercise price granted April 30, 2026 with monthly vesting through May 2030 demonstrates continued equity incentive structure for senior management.
The significant equity grants totaling ~194,150 potential shares reflect substantial commitment to retaining the CMO role, suggesting confidence in the company's therapeutic pipeline and future value creation.

Filed: 2026-05-04

Director John Maraganore acquired 35,948 shares of common stock through conversion of preferred shares (Series B and C) during the company's IPO closing on May 4, 2026, indicating significant insider commitment to the newly public company.
Maraganore received 107,338 warrant shares on January 29, 2026 with a $6 exercise price, vesting over three years in monthly installments through January 2029, representing a substantial equity compensation package aligned with long-term performance.
The preferred stock conversion without additional payment demonstrates automatic conversion upon IPO, which is standard practice but reflects the insider's equity position was established before public markets with favorable terms relative to public offering.
All securities are held directly (Direct ownership) with no indirect holdings reported, providing transparency on the insider's personal stake in the company without complex ownership structures.

Other reports for Hemab Therapeutics Holdings, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.